Evidence map›Paper›PMID 39860102›Full record

ArticleMolecules (Basel, Switzerland)2025

Enhanced Antibacterial Activity of Hydrophobic Modified Lysozyme Against Gram-Negative Bacteria Without Accumulated Resistance.

Zhenhui Li, Song Lin, Mei Zhu, Xiaoman Liu, Xin Huang

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zhenhui LiSchool of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin 150001, China.
Song LinSchool of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin 150001, China.
Mei ZhuSchool of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin 150001, China.
Xiaoman LiuSchool of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin 150001, China.
Xin HuangSchool of Chemistry and Chemical Engineering, Harbin Institute of Technology, Harbin 150001, China.

Funding

China-German Mobility Program M-0470National Natural Science Foundation of China 22475056, 22377022 and 22171058the Fundamental Research Funds for the Central Universities HIT.OCEF.2023040
6 · The paper itself

Abstract

Macromolecule bactericides present challenges such as low biocompatibility and not being biodegradable, so broad-spectrum bactericides without accumulated bacteria resistance are now in urgent demand all over the world. Lysozyme, a kind of wide-spread natural enzyme easily extracted from nature, has become attractive for agriculture and medicine use. However, Gram-negative bacterial strains are highly resistant to natural lysozymes, which limits their practical application. In this study, rather than directly modifying antibacterial-active substance with lysozyme, we show an effective way to improve antibacterial performance by altering the hydrophobic functional groups of natural lysozymes and synthesize a type of hydrophobic modified lysozyme (HML). Compared with other modification methods, the antibacterial performance has been increased by over 50%. We investigated its antibacterial mechanism against Gram-negative bacteria and showed that HML could be used to treat pathogenic bacteria without obvious accumulated resistance appearance, which is a great advantage over commercial antibiotics. Overall, it is anticipated that HML could be potentially applied to food safety, infection therapy, and enzyme-medicine applications.

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialGram-Negative BacteriaMuramidaseHydrophobic and Hydrophilic InteractionsMicrobial Sensitivity TestsAnti-Bacterial AgentsMuramidaseantibacterialbiocompatibilityhydrophobic modificationlysozyme

Identifiers

PMID39860102
PMCPMC11767388

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.